[go: up one dir, main page]

PE20080061A1 - Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3 - Google Patents

Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3

Info

Publication number
PE20080061A1
PE20080061A1 PE2007000515A PE2007000515A PE20080061A1 PE 20080061 A1 PE20080061 A1 PE 20080061A1 PE 2007000515 A PE2007000515 A PE 2007000515A PE 2007000515 A PE2007000515 A PE 2007000515A PE 20080061 A1 PE20080061 A1 PE 20080061A1
Authority
PE
Peru
Prior art keywords
task
alkyl
amida
inhibitors
potassium channels
Prior art date
Application number
PE2007000515A
Other languages
English (en)
Inventor
Joachim Brendel
Heinz Goegelein
Klaus Wirth
Walter Kamm
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006019589A external-priority patent/DE102006019589A1/de
Priority claimed from DE102006049527A external-priority patent/DE102006049527A1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20080061A1 publication Critical patent/PE20080061A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE AMIDA FORMULA (Ia) DONDE R(1) Y R(2) SON CADA UNO R(20)-CrH2r, DONDE R(20) ES H, CH3, CH2F, CF3, ENTRE OTROS; r ES DE 0 A 8; R(3), R(4), R(5) Y R(6) SON CADA UNO H, F, Cl, ALQUILO(C1-C5), CICLOALQUILO(C3-C8), ENTRE OTROS; R(7) ES H O ALQUILO(C1-C4); R(8) ES UN COMPUESTO DE FORMULA (II) O (III) DONDE R9 ES H, OR(28) U OCOR(28), EN DONDE R(28) ES H O ALQUILO(C1-C4); R(10) Y R(11) SON CADA UNO H O ALQUILO(C1-C4); R(12), R(13), R(14) Y R(15) SON CADA UNO H, F, CN, CF3, NO2, CICLOALQUILO(C3-C8), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(BUTIL-1-SULFONILAMINO)-N-[1(R)-(6-METOXIPIRIDIN-3-IL)PRO-PIL]BENZAMIDA, N-(2-PIRIDIN-3-ILETIL)-2'-{[2-(4-METOXIFENIL)ACETILAMINO]-METIL}BIFENIL-2-CARBOXAMIDA, N-(2,4-DIFLUOROBENCIL)-3-(2-{[2-(4-METOXIFENIL)ACETILAMINO]-METIL}FENIL)TIOFENO-2-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LOS CANALES DE POTASIO TASK-1 Y TASK-3 SIENDO UTILES EN EL TRATAMIENTO DE RONQUIDO, SINDROME DE RESISTENCIA DE LAS VIAS SUPERIORES, APNEAS DEL SUENO
PE2007000515A 2006-04-27 2007-04-25 Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3 PE20080061A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006019589A DE102006019589A1 (de) 2006-04-27 2006-04-27 Inhibitoren des TASK-1 und Task-3 Ionenkanals
DE102006049527A DE102006049527A1 (de) 2006-10-20 2006-10-20 Inhibitoren des TASK-1 und TASK-3 Ionenkanals

Publications (1)

Publication Number Publication Date
PE20080061A1 true PE20080061A1 (es) 2008-03-24

Family

ID=38258824

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000515A PE20080061A1 (es) 2006-04-27 2007-04-25 Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3

Country Status (26)

Country Link
US (1) US20090149496A1 (es)
EP (1) EP2012758A2 (es)
JP (1) JP5161871B2 (es)
KR (1) KR101390239B1 (es)
CN (1) CN101636154B (es)
AR (1) AR060822A1 (es)
AU (1) AU2007245891B2 (es)
BR (1) BRPI0710946A2 (es)
CA (1) CA2650391C (es)
CO (1) CO6140023A2 (es)
CR (1) CR10342A (es)
DO (1) DOP2007000083A (es)
EC (1) ECSP088847A (es)
GT (1) GT200800213A (es)
IL (1) IL194868A (es)
MA (1) MA30357B1 (es)
MX (1) MX2008012920A (es)
NO (1) NO20084513L (es)
NZ (1) NZ572231A (es)
PE (1) PE20080061A1 (es)
RU (1) RU2436577C2 (es)
SG (1) SG163543A1 (es)
TN (1) TNSN08431A1 (es)
TW (1) TWI398432B (es)
UY (1) UY30313A1 (es)
WO (1) WO2007124849A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632899A1 (en) 2009-05-29 2020-04-08 RaQualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
CN102459181B (zh) * 2009-06-03 2014-05-07 赛诺菲-安万特德国有限公司 2′-{[2-(4-甲氧基-苯基)-乙酰基氨基]-甲基}-联苯基-2-甲酸(2-吡啶-3-基-乙基)-酰胺的晶相
US8664425B2 (en) * 2010-02-02 2014-03-04 Honeywell International Inc. Bluegreen fluorescent compounds
WO2011103715A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
WO2013037389A1 (en) 2011-09-12 2013-03-21 Sanofi Indanyl-substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
MX2014002968A (es) * 2011-09-12 2014-07-09 Sanofi Sa 4,5,6,7 - tetrahidro - 1h - pirazolo [4,3 -c] piridinas sustituidas con indanilo, su uso como medicamento, y preparaciones farmaceuticas que las comprenden.
SI2755973T1 (sl) 2011-09-16 2016-02-29 Sanofi Substituirani derivati 4,5,6,7-tetrahidro-1H-pirazolo(4,3-C)piridinov, njihova uporaba kot zdravila in farmacevtski preparati, ki jih vsebujejo
WO2013037914A1 (en) 2011-09-16 2013-03-21 Sanofi Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
RU2650111C2 (ru) 2012-02-03 2018-04-09 Санофи Конденсированные пирролдикарбоксамиды и их применение в качестве фармацевтических средств
CN104721832A (zh) * 2013-12-18 2015-06-24 深圳先进技术研究院 携带编码光敏感离子通道蛋白基因的表达载体在制备调控呼吸节律药物中的应用
AU2016232749B2 (en) * 2015-03-18 2021-09-23 The Johns Hopkins University Novel monoclonal antibody inhibitors targeting potassium channel KCNK9
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
JOP20190005A1 (ar) * 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
CN110325110B (zh) 2016-11-10 2022-08-09 纽约州立大学研究基金会 用于气道阻塞的系统、方法和生物标记
EP3558288B1 (en) 2016-12-20 2023-08-16 The University of Chicago L-pag derivatives for treatment of sleep disordered breathing (sdb)
EP3338803A1 (de) * 2016-12-21 2018-06-27 Bayer Pharma Aktiengesellschaft Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
JOP20190148A1 (ar) * 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
JOP20190141A1 (ar) * 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
EP3338764A1 (de) * 2016-12-21 2018-06-27 Bayer Pharma Aktiengesellschaft Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
JOP20190284A1 (ar) * 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
CA3093445A1 (en) 2018-03-08 2019-11-28 Incyte Corporation Aminopyrazine diol compounds as pi3k-.gamma. inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
BR112021008153A2 (pt) * 2018-11-27 2021-08-03 Bayer Aktiengesellschaft processo para a produção de formas de administração farmacêuticas contendo inibidores de canais task-1 e task-3 e seu uso para a terapia de distúrbios respiratórios
CN119462558B (zh) * 2024-10-18 2025-09-19 河南中医药大学 一种布美他尼衍生物及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379666B1 (en) * 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
DE19929076A1 (de) * 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) * 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
AU2001288518A1 (en) * 2000-08-30 2002-03-13 Primecyte, Inc. Methods for treating tumors using sulfonyl compounds
GB2372503A (en) * 2000-10-19 2002-08-28 Glaxo Group Ltd Voltage-gated potassium channel polypeptides
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) * 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
US7781457B2 (en) * 2003-09-23 2010-08-24 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
CA2588517A1 (en) * 2004-12-01 2006-06-08 Devgen N.V. 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family
DE102005028845A1 (de) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
RU2436577C2 (ru) 2011-12-20
CA2650391C (en) 2015-12-15
SG163543A1 (en) 2010-08-30
WO2007124849A2 (en) 2007-11-08
ECSP088847A (es) 2008-11-27
IL194868A (en) 2014-01-30
AU2007245891A1 (en) 2007-11-08
CO6140023A2 (es) 2010-03-19
TNSN08431A1 (en) 2010-04-14
CN101636154A (zh) 2010-01-27
NZ572231A (en) 2010-12-24
CR10342A (es) 2009-01-09
AU2007245891B2 (en) 2012-10-18
DOP2007000083A (es) 2007-11-15
MA30357B1 (fr) 2009-04-01
JP5161871B2 (ja) 2013-03-13
HK1138183A1 (en) 2010-08-20
KR101390239B1 (ko) 2014-04-30
WO2007124849A3 (en) 2009-10-08
CN101636154B (zh) 2011-12-14
US20090149496A1 (en) 2009-06-11
CA2650391A1 (en) 2007-11-08
IL194868A0 (en) 2009-08-03
BRPI0710946A2 (pt) 2012-03-06
GT200800213A (es) 2009-05-04
NO20084513L (no) 2008-11-24
KR20080111509A (ko) 2008-12-23
MX2008012920A (es) 2008-10-15
RU2008146755A (ru) 2010-06-10
EP2012758A2 (en) 2009-01-14
TW200808708A (en) 2008-02-16
TWI398432B (zh) 2013-06-11
UY30313A1 (es) 2007-11-30
JP2009534434A (ja) 2009-09-24
AR060822A1 (es) 2008-07-16

Similar Documents

Publication Publication Date Title
PE20080061A1 (es) Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3
PE20090641A1 (es) Amidas heterociclicas
PE20141375A1 (es) Activadores de glucoquinasa
PE20081385A1 (es) Derivados de nicotinamida
PE20121354A1 (es) Inhibidores del virus de la hepatitis c
US7105567B2 (en) 3-substituted urea derivatives and medicinal use thereof
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
ME02696B (me) MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
AR072490A1 (es) 1,2,5- oxadiazoles como inhibidores de indolamina 2,3 dioxigenasa
PE20090727A1 (es) DERIVADOS DE AMIDA COMO INHIBIDORES DE NaV1.7
PE20091096A1 (es) Compuestos organicos
BRPI0507506A (pt) compostos
EA201070619A1 (ru) Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений
PE20090694A1 (es) Compuestos moduladores de sirtuinas
PE20121496A1 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
EA201071019A1 (ru) Кристаллические формы производных фениламинопиримидина
PE20110905A1 (es) Arilpirrolidinas pesticidas
AR062299A1 (es) Derivados de bencimidazol
CO5700757A2 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20081383A1 (es) Inhibidores benzoimidazolicos de trpv1
PE20061117A1 (es) DERIVADOS DE FENILGLICINAMIDA COMO INHIBIDORES DEL FACTOR VIIa
PE20081779A1 (es) Derivados de nicotinamida

Legal Events

Date Code Title Description
FC Refusal